Holen Sie sich die Stockscreener-App
0.718
0.00%
0.00
Metavia Inc Aktie (MTVA) Neueste Nachrichten
MetaVia doses first patient in 48 mg MAD cohort of its Phase 1 trial - MSN
MetaVia Initiates Phase 1 Trial for Obesity Drug - TipRanks
MetaVia begins dosing in higher-dose cohort of obesity drug trial, top-line data expected Q4 2025 - grafa.com
MetaVia's Novel Obesity Drug Achieves 4.3% Weight Loss Without Titration, Outperforming GLP-1 Tolerability - Stock Titan
MetaVia registers 14.1M shares for resale - MSN
MetaVia Holds Virtual Annual Stockholders Meeting - TipRanks
Clinical Data: MetaVia's Novel MASH Drug Combo Achieves Breakthrough 94% Response Rate in Preclinical Study - Stock Titan
MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th - GlobeNewswire
MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions - Eastern Progress
MetaVia Sees Obesity Opportunities Despite Challenging US Market - insights.citeline.com
MTVA stock touches 52-week low at $0.64 amid market challenges By Investing.com - Investing.com South Africa
MetaVia Inc. receives Nasdaq non-compliance notice - Investing.com Australia
MetaVia Faces Nasdaq Delisting Notice for Low Stock Price - TipRanks
MTVA stock touches 52-week low at $0.64 amid market challenges - Investing.com Nigeria
MetaVia Reports Progress in Obesity and MASH Treatments - TipRanks
MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study… - Zacks Small Cap Research
MetaVia Updates Corporate Presentation on DA-1726 Progress - TipRanks
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream - GlobeNewswire
Major Investment Alert: DONG-A ST CO., LTD Boosts Stake in MetaVia! - TipRanks
MetaVia (NASDAQ:MTVA) Price Target Lowered to $3.00 at Maxim Group - Defense World
Maxim Group Lowers MetaVia (MTVA) Price Target to $3.00 | MTVA S - GuruFocus
MetaVia price target lowered to $3 from $6 at Maxim - TipRanks
MetaVia (MTVA) Price Target Cut as Analyst Highlights Future Pro - GuruFocus
MetaVia (MTVA) Price Target Cut as Analyst Highlights Future Prospects | MTVA Stock News - GuruFocus
MetaVia Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update - WV News
MetaVia Completes $10 Million Private Placement - TipRanks
MetaVia launches $10M private placement - MSN
MetaVia secures $10 million in private placement - Investing.com
MetaVia (MTVA) to Raise $10M Through Private Placement | MTVA St - GuruFocus
MetaVia secures $10 million in private placement By Investing.com - Investing.com South Africa
MetaVia announces $10M private placement - TipRanks
MetaVia Inc. announced that it expects to receive $9.995395 million in funding - marketscreener.com
Metavia Announces $10 Million Private Placement Priced At-The-Market Under Nasdaq Rules - marketscreener.com
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules - Eastern Progress
MTVAMetaVia Inc Latest Stock News & Market Updates - Stock Titan
MetaVia Unveils Promising DA-1241 Trial Results - TipRanks
Asian shares get a lift from plans for China-US trade talks, Beijing stimulus moves - WFMZ.com
Metavia Presents Data On DA-1241, A GPR119 Agonist, Demonstrating Both Hepatoprotective And Glucose-Regulating Effects In Patients With Presumed MASH, At The EASL Congress 2025 - MENAFN.com
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 - Stock Titan
Senate confirms Bisignano to lead Social Security Administration as agency faces DOGE overhaul - WFMZ.com
Trump’s meme coin business racks up fees as buyers jump at the chance for access to the president - WFMZ.com
MetaVia Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating - TipRanks
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial By Investing.com - Investing.com South Africa
Copper Miner Rallies as Takeover Buzz Sparks Investor Optimism - The Globe and Mail
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - Eastern Progress
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial - Investing.com
MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com
2.10%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):